DOCSLIB.ORG

Design, Synthesis, and Pharmacological Evaluation Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Design, Synthesis, and Pharmacological Evaluation Of University of Wollongong Research Online University of Wollongong Thesis Collection University of Wollongong Thesis Collections 2012 Design, Synthesis, and Pharmacological Evaluation of Novel Antipsychotic Drugs Based on Olanzapine That Display Reduced Weight Gain and Metabolic Side Effects Somayeh Jafari University of Wollongong Recommended Citation Jafari, Somayeh, Design, Synthesis, and Pharmacological Evaluation of Novel Antipsychotic Drugs Based on Olanzapine That Display Reduced Weight Gain and Metabolic Side Effects, Doctor of Philosophy thesis, School of Health Sciences, University of Wollongong, 2012. http://ro.uow.edu.au/theses/3582 Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: [email protected] Design, Synthesis, and Pharmacological Evaluation of Novel Antipsychotic Drugs Based on Olanzapine That Display Reduced Weight Gain and Metabolic Side Effects A thesis submitted in fulfillment of the requirements for the award of the degree of Doctor of Philosophy From The University of Wollongong By Somayeh Jafari Masters of Science (MedChem) Supervisors: Prof. Xu-Feng Huang Dr Francesca Fernandez-Enright School of Health Sciences March, 2012 CERTIFICATION I, Somayeh Jafari, declare that this thesis, submitted in full fulfillment of the requirements for the award of Doctor of Philosophy, in the School of Health Sciences, Faculty of Health and Behavioral Sciences, University of Wollongong, is wholly my own work unless referenced or acknowledged. The document has not been submitted for qualifications at any other academic institution. Somayeh Jafari March, 2012 i TABLE OF CONTENTS CERTIFICATION i TABLE OF CONTENTS ii LIST OF FIGURES vi LIST OF SCHEMES vii LIST OF TABLES viii LIST OF ABBREVIATINS ix PUBLICATIONS xii ACKNOWLEDGEMENTS xiii ABSTRACT xv CHAPTER 1: INTRODUCTION 1 1.1 Contribution of Structure to Therapeutic Actions 2 1.1.1 Phenothiazines and Thioxanthenes 9 1.1.2 Butyrophenones, Diphenylbutylpiperidines and Benzamides 9 1.1.3 Benzisoxazolepiperidines and Indoles 10 1.1.4 Dibenzodiazepines, Thienobenzodiazepines and Dibenzothiazepines 11 1.1.5 Phenylpiperazines and Azapirones 12 1.1.6 Effectiveness of Antipsychotic Drugs in CATIE Study 13 1.2 The Metabolic Side Effects of Antipsychotics 14 1.3 Potential Mechanisms of Antipsychotic-Induced Weight Gain and 19 Discussion of SAR 1.4 Conclusions and Future Prospects 26 1.5 Aims of This Project 27 ii CHAPTER 2: SYNTHESIS AND SAR STUDY OF 29 NOVEL POTENTIAL ANTIPSYCHOTICS 2.1 Background 29 2.2 Synthesis of Novel Olz Derivatives 35 2.3 General Procedures 41 2.3.1 Experimental Procedures, Reagents, and Solvents 41 2.3.2 Microwave Reactions 41 2.3.3 Chromatography 41 2.4 Characterization and Instrumentation 42 2.4.1 1H- and 13C-Nuclear Magnetic Resonance (NMR) Spectroscopy 42 2.4.2 Infrared Spectrometry (IR) 43 2.4.3 Mass Spectrometry (MS) 43 2.4.4 Melting Points 43 2.5 Synthesis of OlzEt 44 2.6 Synthesis of OlzHomo 46 2.7 Synthesis of MeHomo 48 2.8 Characterization of Compound 3 50 2.9 In Vitro Receptor Binding Profiles and SAR Study of Potential 51 Antipsychotics 2.9.1 Method 51 2.9.2 Results 53 2.9.3 Discussion 54 2.9.4 Conclusion 56 iii CHAPTER 3: THE EFFECT OF OLZ,OLZET, 59 AND OlzHOMO ON WEIGHT GAIN AND METABOLIC SIDE EFFECTS 3.1 Background 59 3.2 Materials and Methods 61 3.2.1 Animals and drug treatment regime 3.2.2 Hormonal and post mortem measurement 62 3.2.3 Radioligand binding assay 64 3.2.4 Data analysis 65 3.3 Results 65 3.3.1 Body weight gain, food and water intake 65 3.3.2 Fat deposition 67 3.3.3 Plasma hormonal level 67 3.3.4 Alterations in H1, D2, and 5HT2A receptor densities 68 3.4 Discussion 76 3.4.1 Prevention of weight gain and adiposity following OlzEt and 76 OlzHomo regimes 3.4.2 A study on neurochemical alterations following the treatments 80 with Olz, OlzEt, and OlzHomo 3.5 Conclusion 86 CHAPTER 4: BEHAVIOURAL STUDY: 87 ACOMPARISION BETWEEN OLZ, OLZET, AND OLZHOMO 4.1 Introduction 87 4.2 Materials and Methods 89 4.2.1 Animals and drug treatment regimes 89 4.2.2 Behavioural analysis and post mortem measurement 90 4.2.3 Data analysis 92 4.2.3 Radioligand binding assay 92 4.3 Results 93 4.3.1 Behavioural testing 93 iv 4.3.2 Alteration in D2 and 5HT2A receptor densities 93 4.4 Discussion 97 4.5 Conclusion 100 CHAPTER 5: GENERAL CONCLUSIONS AND FUTURE PROSPECTS 5.1 Conclusion 102 5.2 Future Directions 105 REFERENCES 108 v LIST OF FIGURES Figure 2.1: a) Olz mapped into the proposed H1 agonist 30 pharmacophore model; b) Structure of Olz showing atom numbering Figure 2.2: Chemical structures of compounds 1 (OlzEt), 2, and 3 30 Figure 2.3: Chemical structure of Olz analogues modified at position 34 C-4 Figure 2.4: Chemical structure of dimer 16 36 Figure 2.5: Structural parameters for bioactive conformations of 58 tetracyclic thienobenzodiazepines Figure 3.1: Oral administration of Olz to a female Sprague Dawley 63 rat using the sweet cookie-dough pellet method Figure 3.2: Total body weight gain (g), Total food intake (g), and 70 Energy efficiency in female Sprague Dawley rat treated with Olz, OlzEt, OlzHomo (3 mg/kg or 6 mg/kg), or vehicle (Control) Figure 3.3: Cumulative body weight gain (g), cumulative food 71 intake (g), and cumulative water intake (ml) in female Sprague Dawley rat treated with Olz, OlzEt, OlzHomo, or vehicle (Control) Figure 3.4: Plasma insulin (PM), Leptin (PM), Adiponectin (pg/ml) 72 in female Sprague Dawley rat treated with Olz, OlzEt, OlzHomo, or vehicle (Control) Figure 3.5 (a): Systematic overview of the potential neuropathology 84 underlying increased food intake and obesity pertinent to schizophrenia Figure 3.5 (b): Systematic overview of the potential neuropathology 85 underlying increased food intake and obesity following treatment with Olz Figure 4.1: Rat performing in the open field test 91 vi LIST OF SCHEME Scheme 2.1: Vilsmeier-Haack reaction of Olz 32 Scheme 2.2: Synthesis of compound 2 32 Scheme 2.3: Synthesis of compounds OlzEt 1, OlzHomo 8b, and MeHomo 8a 35 Scheme 2.4: Synthesis of compound 9b 40 vii LIST OF TABLES Table 1.1: Chemical structures and receptor binding affinity profiles of 5 antipsychotics Table 1.2: Preclinical studies on potential future antipsychotics 24 Table 2.1: Various attempted conditions for N-10 protection of Olz 33 Table 2.2: Binding affinities of Olz, compounds 3, OlzEt, OlzHomo, and 54 MeHomo for 5HT2A, D2, and H1 receptors in Sprague Dawley rats Table 3.1: Mean body weight and fat pad mass in female Sprague Dawley 73 rats Table 3.2: H1, D2, and 5HT2A receptor specific densities in the hypothalamus, 74 striatum, and prefrontal cortex of female Sprague Dawley rats Table 3.3: Results of correlation and regression analysis 75 Table 4.1: Open field testing in male Sprague Dawley rats following 2 weeks 95 treatment with Olz, OlzEt , OlzHomo, or vehicle (Control) Table 4.2: D2 and 5HT2A receptor specific densities in the striatum and 96 prefrontal cortex of male Sprague Dawley rats viii LIST OF ABBREVIATIONS 5-HT2 5-hydroxytryptamine A Atypical A Adrenergic receptor AMPK Adenosine monophosphate-activated protein kinase ANOVA Analysis of variance BAT Brown adipose tissue BBB Blood-brain barrier Boc tert-Butoxycarbonyl Calcd Calculated CATIE Clinical antipsychotic trial on intervention effectiveness Cbz Benzyloxycarbonyl CI Chemical ionization Ci Curie CPM Count per minute d Doublet dd Double of doublets D Dopamine receptor DCM Dichloromethane DEPT Distortionless enhancement by polarisation transfer DMF N,N-dimethylformamide DMPK Drug Metabolism/Pharmacokinetics DMSO Dimethylsulfoxide DOPAC Dihyroxyphenylacetic acid dt Double of triplet EDTA Ethyl(carboxymethyl)amino]acetic acid ED50 Median effective dose EI Electron impact EPS Extrapyramidal symptoms equiv Equivalents ESI Electrospray ionization ix GCOSY Gradient correlation spectroscopy GHMBC Gradient heteronuclear multiple bond correlation GHSQC Gradient heteronuclear single quantum correlation Glu Glutamate h Hours H Histamine receptor H Hydrogen/proton HPLC High performance liquid chromatography HRMS High resolution mass spectrometry Hz Hertz IC50 Inhibitory concentration (half maximal) J Coupling constant Kg Kilogram Ki Inhibition constant Kcal Kilo calories LRMS Low resolution mass spectrometry m Multiplet M Molar M Muscarinic receptor MHz Mega hertz min Minutes mL Milliliters mmol Millimole m.p. Melting point MS Mass spectrometry MW Molecular weight m/z Mass to charge ratio nM Nanomolar NMDA N-methyl-D-aspartate acid NMR Nuclear magnetic resonance Olz Olanzapine PCP Phencyclidine x PET Positron-emission tomography pH Potential of hydrogen PPM Part per million PTLC Preparative thin layer chromatogeraphy q Quartet quin Quintet rt Room temperature Ref Reference Rf Retention factor s Singlet SAR Structure activity relationship SDA Serotonin-dopamine antagonist SES 2-(trimethylsilyl) ethyl sulfonyl SREBP-1 Sterol regulatory element binding protein-1 t Triplet T Typical TD Tardive dyskinesia THF Tetrahydofuran TLC Thin layer chromatogeraphy TMS Tetramethylsilane TRIS Tris(hydroxymethyl)aminomethane UCP Uncoupling protein UV Ultraviolet µL Microliter δ Chemical shift (in parts per million, downfield from TMS) xi PUBLICATIONS The following publications and presentations have arisen directly from a work conducted for this thesis. Publication in Referred Journals Jafari S, Fernandez-Enright F, and Huang X-F. Structural contribution of antipsychotic drugs to their therapeutic profiles and methabolic side effects. Journal of Neurochemistry120: 371–384, 2012. (Chapter 1) Jafari S, Bouillon ME, Huang X-F, Pyne SG, and Fernandez-Enright F. Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio. BMC Pharmacology 12: 8, 2012 (Chapter 2) Jafari S, Huang X-F, and Fernandez-Enright F. In vivo pharmacological evaluations of novel olanzapine analogues in rats: potential novel antipsychotic drugs with lower metabolic side effect.
Load more

Recommended publications
  • NIH Public Access Author Manuscript Bioorg Med Chem
    NIH Public Access Author Manuscript Bioorg Med Chem. Author manuscript; available in PMC 2013 February 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Bioorg Med Chem. 2012 February 1; 20(3): 1291–1297. doi:10.1016/j.bmc.2011.12.019. Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents Kwakye Pepraha, Xue Y. Zhua, Suresh V. K. Eyunnia, Vincent Setolab, Bryan L. Rothb, and Seth Y. Ablordeppey*,a aDivision of Basic Pharmaceutical Sciences, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Tallahassee, FL 32307, USA bDepartment of Pharmacology, Medicinal Chemistry and Psychiatry, University of North Carolina at Chapel Hill, School of Medicine, NC 27599, USA Abstract Using haloperidol as a scaffold, new agents were designed to investigate the structural contributions of various groups to binding at CNS receptors associated with atypical antipsychotic pharmacology. It is clear that each pharmacophoric group, the butyrophenone, the piperidine and the 4-chlorophenyl moieties contributes to changes in binding to the receptors of interest. This strategy has resulted in the identification of several new agents, compounds 16, 18, 19, 23, 24 and 25, with binding profiles which satisfy our stated criteria for agents to act as potential atypical antipsychotics. This research demonstrates that haloperidol can serve as a useful lead in the identification and design of new agents that target multiple receptors
    [Show full text]
  • Bifeprunox: a Novel Antipsychotic Agent with Partial Agonist Properties at Dopamine D2 and Serotonin 5-HT1A Receptors
    DRUG EVALUATION Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors Marie-Louise G Most second-generation, atypical, dopamine (DA) D2/5-HT2 blocking antipsychotics still Wadenberg induce extrapyramidal side effects (EPS) in higher doses. Weight gain and metabolic University of Kalmar, disturbances are also a problem, and negative and cognitive symptoms have not been Department of Natural Sciences, Norra Vagen 49, sufficiently addressed. The current brain DA mesolimbic hyperactive/mesocortical SE-391 82 Kalmar, Sweden hypoactive hypothesis of schizophrenia suggests that DA D2/5-HT1A receptor partial agonist Tel.: +46 480 446 277; properties may be more efficacious with less side effects. DA D2 receptor partial agonists Fax: +46 480 446 244; may stabilize a hyperactive/hypoactive DA condition. Additional 5-HT stimulation may marie-louise.wadenberg@ 1A hik.se enhance therapeutic efficacy and also improve EPS liability profile. In clinical trials in schizophrenic patients, the novel DA D2/5-HT1A partial agonist bifeprunox indeed demonstrates therapeutic efficacy, a safe EPS profile and appears beneficial regarding weight gain, prolactin, blood lipid and glucose levels and cardiac rhythm. The data on bifeprunox are promising and suggest that combined DA D2/5-HT1A partial agonism may well be important properties for future-generation antipsychotics. Bifeprunox, a novel antipsychotic agent with a (DA D1, D2, D4, 5-HT2A/C, 5-HT1A, hista- so-called third-generation atypical pharmacolog- mine H1, α1, α2, cholinergic muscarinic recep- ical profile, is currently in clinical trials and tor affinity) and comparatively lower affinity for expected to launch as a schizophrenia therapy in the DA D2 receptor than traditional APDs.
    [Show full text]
  • HTR1A Polymorphisms and Clinical Efficacy Of
    International Journal of Neuropsychopharmacology, (2016) 19(5): 1–10 doi:10.1093/ijnp/pyv125 Advance Access publication November 14, 2015 Research Article research article HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis Yoshiteru Takekita, MD, PhD; Chiara Fabbri, MD; Masaki Kato, MD, PhD; Yosuke Koshikawa, MA; Aran Tajika, MD; Toshihiko Kinoshita, MD, PhD; Alessandro Serretti, MD, PhD Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy (Drs Takekita, Fabbri, and Serretti); Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan (Drs Takekita, Kato, Koshikawa, and Kinoshita); Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan (Dr Tajika). Correspondence: Yoshiteru Takekita, MD, PhD, Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Viale Carlo Pepoli 5, Bologna, 40123, Italy ([email protected]). Abstract Background: This meta-analysis was conducted to evaluate whether HTR1A gene polymorphisms impact the efficacy of antipsychotic drugs in patients with schizophrenia. Methods: Candidate gene studies that were published in English up to August 6, 2015 were identified by a literature search of PubMed, Web of Science, and Google scholar. Data were pooled from individual clinical trials considering overall symptoms, positive symptoms and negative symptoms, and standard mean differences were calculated by applying a random-effects model. Results: The present meta-analysis included a total of 1281 patients from 10 studies. Three polymorphisms of HTR1A (rs6295, rs878567, and rs1423691) were selected for the analysis. In the pooled data from all studies, none of these HTR1A polymorphisms correlated significantly with either overall symptoms or positive symptoms.
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • (KPIC) PPO and Out-Of- Area Indemnity (OOA) Drug Formulary with Specialty Drug Tier
    Kaiser Permanente Insurance Company (KPIC) PPO and Out-of- Area Indemnity (OOA) Drug Formulary with Specialty Drug Tier This Drug Formulary was updated: September 1, 2021 NOTE: This drug formulary is updated often and is subject to change. Upon revision, all previous versions of the drug formulary are no longer in effect. This document contains information regarding the drugs that are covered when you participate in the California Nongrandfathered PPO and Out-of- Area Indemnity (OOA) Health Insurance Plans with specialty drug tier offered by Kaiser Permanente Insurance Company (KPIC) and fill your prescription at a MedImpact network pharmacy. Access to the most current version of the Formulary can be obtained by visiting kp.org/kpic-ca-rx-ppo-ngf. For help understanding your KPIC insurance plan benefits, including cost sharing for drugs under the prescription drug benefit and under the medical benefit, please call 1-800-788-0710 or 711 (TTY) Monday through Friday, 7a.m. to 7p.m. For help with this Formulary, including the processes for submitting an exception request and requesting prior authorization and step therapy exceptions, please call MedImpact 24 hours a day, 7 days a week, at 1-800-788-2949 or 711 (TTY). For cost sharing information for the outpatient prescription drug benefits in your specific plan, please visit: kp.org/kpic-ca-rx-ppo-ngf. For help in your preferred language, please see the Kaiser Permanente Insurance Company Notice of Language Assistance in this document. KPIC PPO NGF Table of Contents Informational Section................................................................................................................................2
    [Show full text]
  • The Role of Kinetic Context in Apparent Biased Agonism at Gpcrs
    ARTICLE Received 2 Jul 2015 | Accepted 27 Jan 2016 | Published 24 Feb 2016 DOI: 10.1038/ncomms10842 OPEN The role of kinetic context in apparent biased agonism at GPCRs Carmen Klein Herenbrink1, David A. Sykes2, Prashant Donthamsetti3,4, Meritxell Canals1, Thomas Coudrat1, Jeremy Shonberg5, Peter J. Scammells5, Ben Capuano5, Patrick M. Sexton1, Steven J. Charlton2, Jonathan A. Javitch3,4,6, Arthur Christopoulos1 & J Robert Lane1 Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing pathway-specific drugs that avoid on-target side effects. This mechanism is usually inferred from pharmaco- logical data with the assumption that the confounding influences of observational (that is, assay dependent) and system (that is, cell background dependent) bias are excluded by experimental design and analysis. Here we reveal that ‘kinetic context’, as determined by ligand-binding kinetics and the temporal pattern of receptor-signalling processes, can have a profound influence on the apparent bias of a series of agonists for the dopamine D2 receptor and can even lead to reversals in the direction of bias. We propose that kinetic context must be acknowledged in the design and interpretation of studies of biased agonism. 1 Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia. 2 Cell Signalling Research Group, School of Life Sciences, University of Nottingham, Queen’s Medical Centre, Nottingham NG7 2UH, UK. 3 Departments of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA. 4 Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
    [Show full text]
  • Symposium: the Role of 5-HT1AR in Pathophysiology and Treatment Of
    Abstracts for oral sessions / European Psychiatry 23 (2008) S1eS80 S61 S51.05 Our transgenic mice showed no overall cognitive deficit. As a ten- Treatment-seeking gamblers and Parkinson’s disease: Case reports dency, inhibitory avoidance retention was impaired in transgenic mice compared to wild-type controls. Both genotypes showed similar O. Simon. Center for Pathological Gambling, Community Psychiatry spatial learning abilities in the Morris water maze and habituated to Services, Department of Adult Psychiatry, University Hospital of the hole-board in a comparable manner. Anterograde amnesia in- Lausanne, Lausanne, Switzerland duced by 8-OH-DPAT was in transgenic mice already apparent in a third of the dose used for wild-type mice. Retrograde amnesia could Pathological gambling (PG) is a rare but well-established behavioural not be triggered. disorders of Parkinson’s disease (PD) patients treated with dopamine agonist. We investigate the chronological relationship between PD Since the transgenic mice show untreated a rather normal be- and diagnosis of PG within treatment-seeking gamblers. haviour, we assume that they possess compensatory mechanisms. However, after activation of the postsynaptic 5-HT1A-receptors Sample and Methods: From 174 consecutively admitted patho- the differences between wild-type and transgenic mice became logical gamblers we identified 4 patients with PD. Standardized med- more clear. Hence, our findings suggest that the cortical and hip- ical records include socio-demographic characteristics, past gaming pocampal 5-HT1A-receptors play rather a modulatory role in behaviours and gambling-treatment modalities as well as the evolu- learning. tion of PD and the pro-dopaminergic medication history. Results: All four patients developed PG after the onset of PD S48.02 treatment.
    [Show full text]
  • Traditional Open Drug List
    Traditional Open Drug List Drug list — Four Tier Drug Plan Your prescription benefit comes with a drug list, which is also called a formulary. This list is made up of brand-name and generic prescription drugs approved by the U.S. Food & Drug Administration (FDA). Here are a few things to remember about the list: o You and your doctor can use it as a guide to choose drugs that are best for you. Drugs that aren’t on this list may not be covered by your plan and may cost you more out of pocket. o Your coverage has limitations and exclusions, which means there are certain rules about what's covered by your plan and what isn't. To find out more, view your Certificate/Evidence of Coverage or your Summary Plan Description by logging in at anthem.com and go to My Plan ->Benefits-> Plan Documents. o To help you see how the drug list works with your drug benefit, we've included some frequently asked questions (FAQ) about how the list is set up and what to do if a drug you take isn't on it. o This booklet is updated on a quarterly basis. To view the most up-to-date list of drugs for your plan - including drugs that have been added, generic drugs and more - log in at anthem.com and choose Prescription Benefits. If you have questions about your pharmacy benefits, we're here to help. Just call us at the Pharmacy Member Services number on your ID card. 05374MUMENABS Traditional Open Drug List What is a drug list? The drug list, also called a formulary, is a list of prescription medicines your plan covers.
    [Show full text]
  • Identification, Isolation, Synthesis and Characterization of Impurities of Quetiapine Fumarate
    ORIGINAL ARTICLES Aurobindo Pharma Ltd. Research Centre1, Bachupally, J. N. T. University2, Kukatpally, Hyderabad, India Identification, isolation, synthesis and characterization of impurities of quetiapine fumarate Ch. Bharathi1, K. J. Prabahar1, Ch. S. Prasad1, M. Srinivasa Rao1, G. N. Trinadhachary1, V. K. Handa1, R. Dandala1, A. Naidu2 Received May 28, 2007, accepted June 18, 2007 Ramesh Dandala, Senior Vice-President, A. P. L. Research centre, 313, Bachupally, Hyderabad 500072, India [email protected] Pharmazie 63: 14–19 (2008) doi: 10.1691/ph.2008.7174 In the process for the preparation of quetiapine fumarate (1), six unknown impurities and one known impurity (intermediate) were identified ranging from 0.05–0.15% by reverse-phase HPLC. These impu- rities were isolated from crude samples using reverse-phase preparative HPLC. Based on the spectral data, the impurities were characterized as 2-[4-dibenzo[b,f ][1,4]thiazepine-11-yl-1-piperazinyl]1-2-etha- nol (impurity I, desethanol quetiapine), 11-[(N-formyl)-1-piperazinyl]-dibenzo[b,f ][1,4]thiazepine (impur- ity II, N-formyl piperazinyl thiazepine), 2-(2-hydroxy ethoxy)ethyl-2-[2-[4-dibenzo[b,f ][1,4]thiazepine-11- piperazinyl-1-carboxylate (impurity III, quetiapine carboxylate), 11-[4-ethyl-1-piperazinyl]dibenzo [b,f ][1,4] thiazepine (impurity IV, ethylpiperazinyl thiazepine), 2-[2-(4-dibenzo[b,f ][1,4]thiazepin-11-yl-1-piperazi- nyl)ethoxy]1-ethyl ethanol [impurity V, ethyl quetiapine), 1,4-bis[dibenzo[b,f ][1,4]thiazepine-11-yl] piper- azine [impurity VI, bis(dibenzo)piperazine]. The known impurity was an intermediate, 11-piperazinyl- dibenzo [b,f ][1,4]thiazepine (piperazinyl thiazepine).
    [Show full text]
  • Anthem Blue Cross Prescription Formulary List
    National Drug List Drug list — Three Tier Drug Plan Your prescription benefit comes with a drug list, which is also called a formulary. This list is made up of brand-name and generic prescription drugs approved by the U.S. Food & Drug Administration (FDA). We’re here to help. If you are a current Anthem member with questions about your pharmacy benefits, we're here to help. Just call us at the Member Services number on your ID card. The plan names to which this formulary applies are shown below. Solution PPO 1500/15/20 $5/$15/$50/$65/30% to $250 after deductible Solution PPO 2000/20/20 $5/$20/$30/$50/30% to $250 Solution PPO 2500/25/20 $5/$20/$40/$60/30% to $250 Solution PPO 3500/30/30 $5/$20/$40/$60/30% to $250 Rx ded $150 Solution PPO 4500/30/30 $5/$20/$40/$75/30% to $250 Solution PPO 5500/30/30 $5/$20/$40/$75/30% to $250 Rx ded $250 $5/$15/$25/$45/30% to $250 $5/$20/$50/$65/30% to $250 Rx ded $500 $5/$15/$30/$50/30% to $250 $5/$20/$50/$70/30% to $250 $5/$15/$40/$60/30% to $250 $5/$20/$50/$70/30% to $250 after deductible Here are a few things to remember: o You can view and search our current drug lists when you visit anthem.com/ca/pharmacyinformation. Please note: The formulary is subject to change and all previous versions of the formulary are no longer in effect.
    [Show full text]
  • Antipsychotics
    The Fut ure of Antipsychotic Therapy (page 7 in syllabus) Stepp,,hen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry Universityyg of California, San Diego School of Medicine Honorary Visiting Senior Fellow, Cambridge University, UK Sppyonsored by the Neuroscience Education Institute Additionally sponsored by the American Society for the Advancement of Pharmacotherapy This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. Copyright © 2011 Neuroscience Education Institute. All rights reserved. Individual Disclosure Statement Faculty Editor / Presenter Stephen M. Stahl, MD, PhD, is an adjunct professor in the department of psychiatry at the University of California, San Diego School of Medicine, and an honorary visiting senior fellow at the University of Cambridge in the UK. Grant/Research: AstraZeneca, BioMarin, Dainippon Sumitomo, Dey, Forest, Genomind, Lilly, Merck, Pamlab, Pfizer, PGxHealth/Trovis, Schering-Plough, Sepracor/Sunovion, Servier, Shire, Torrent Consultant/Advisor: Advent, Alkermes, Arena, AstraZeneca, AVANIR, BioMarin, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, CeNeRx, Cypress, Dainippon Sumitomo, Dey, Forest, Genomind, Janssen, Jazz, Labopharm, Lilly, Lundbeck, Merck, Neuronetics, Novartis, Ono, Orexigen, Otsuka, Pamlab, Pfizer, PGxHealth/Trovis, Rexahn, Roche, Royalty, Schering-Plough, Servier, Shire, Solvay/Abbott, Sunovion/Sepracor, Valeant, VIVUS, Speakers Bureau: Dainippon Sumitomo, Forest, Lilly, Merck, Pamlab, Pfizer, Sepracor/Sunovion, Servier, Wyeth Copyright © 2011 Neuroscience Education Institute. All rights reserved. Learninggj Objectives • Differentiate antipsychotic drugs from each other on the basis of their pharmacological mechanisms and their associated therapeutic and side effects • Integrate novel treatment approaches into clinical practice according to best practices guidelines • Identify novel therapeutic options currently being researched for the treatment of schizophrenia Copyright © 2011 Neuroscience Education Institute.
    [Show full text]
  • Central Nervous System 5 Objectives
    B978-0-7234-3630-0.00005-4, 00005 Central nervous system 5 Objectives After reading this chapter, you will: ● Understand the functions of the central nervous system and the diseases that can occur ● Know the drug classes used to treat these conditions, their mechanisms of action and adverse effects. Parkinson’s disease is progressive, with continued BASIC CONCEPTS loss of dopaminergic neurons in the substantia nigra correlating with worsening of clinical symptoms. The The central nervous system consists of the brain and the possibility of a neurotoxic cause has been strengthe- spinal cord, which are continuous with one another. ned by the finding that 1-methyl-4-phenyl-1,2,3, The brain is composed of the cerebrum (which consists 6-tetrahydropyridine (MPTP), a chemical contaminant of the frontal, temporal, parietal and occipital lobes), of heroin, causes irreversible damage to the nigrostriatal the diencephalon (which includes the thalamus and dopaminergic pathway. Thus, this damage can lead hypothalamus), the brainstem (which consists of the mid- to the development of symptoms similar to those of brain, pons and medulla oblongata) and the cerebellum. idiopathic Parkinson’s disease. Drugs that block The brain functions to interpret sensory information dopamine receptors can also induce parkinsonism. obtained about the internal and external environments Neuroleptic drugs (p. 000) used in the treatment of TS1 and send messages to effector organs in response to a schizophrenia can produce parkinsonian symptoms as situation. Different parts of the brain are associated an adverse effect. Rare causes of parkinsonism are cere- with specific functions (Fig. 5.1). However, the brain is a bral ischaemia (progressive atherosclerosis or stroke), complex organ and is not yet completely understood.
    [Show full text]